Microbot Medical Commenced its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System GLP Pre-Clinical Trial Commenced at a Leading Research Institute by Global Leaders in the Endovascular Space

Medical Commenced its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System

Pre-Clinical Trial Commenced at a Leading Research Institute by Global Leaders in the Endovascular Space

Mass., September 12, 2022 - Microbot Medical Inc. (Nasdaq: MBOT) announces the commencement of its GLP Pre-Clinical Trial for

the LIBERTY Robotic System at a world-class MedTech research laboratory. The study is being conducted by top Key Opinion Leaders (KOLs).

much anticipated and important milestone represents the first step in our path to achieve regulatory approvals as we aim to transform

the world of surgical robotics in general, and specifically in the endovascular space," commented Harel Gadot, Chairman, CEO and

President. "We believe, based on the multiple successful feasibility studies performed to date, that we will be able to successfully

meet the study's endpoints, allowing us to continue progressing toward various regulatory approvals."

Microbot Medical Inc.

Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,

focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms

provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for

patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available

at http://www.microbotmedical.com.

as to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities

for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or

prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform

Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that

contain words such as "will," "believes," "plans," "anticipates," "expects"

and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and

uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of potential

products, including LIBERTY and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies,

any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct the SCS's EFS which

could adversely affect or delay the EFS, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory

approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual

property rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors" in

Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's

web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required